FY2025 EPS Estimates for YMAB Increased by Analyst

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Investment analysts at Brookline Capital Management boosted their FY2025 earnings per share (EPS) estimates for shares of Y-mAbs Therapeutics in a research report issued on Tuesday, May 13th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings of ($0.81) per share for the year, up from their prior forecast of ($0.93). The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.65) per share. Brookline Capital Management also issued estimates for Y-mAbs Therapeutics’ Q4 2025 earnings at ($0.19) EPS.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.10. The business had revenue of $20.90 million for the quarter, compared to analysts’ expectations of $19.97 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%.

YMAB has been the topic of a number of other reports. Bank of America cut Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 price target on the stock. in a research note on Tuesday, April 22nd. HC Wainwright decreased their price target on Y-mAbs Therapeutics from $22.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. Oppenheimer reduced their target price on Y-mAbs Therapeutics from $21.00 to $20.00 and set an “outperform” rating on the stock in a research note on Wednesday. Wedbush restated an “outperform” rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a report on Monday, March 3rd. Finally, Truist Financial cut their price target on shares of Y-mAbs Therapeutics from $18.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday. Two equities research analysts have rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $16.70.

Y-mAbs Therapeutics Price Performance

Shares of Y-mAbs Therapeutics stock opened at $4.10 on Friday. The business’s 50 day simple moving average is $4.47 and its two-hundred day simple moving average is $7.05. The stock has a market capitalization of $185.64 million, a P/E ratio of -7.59 and a beta of 0.53. Y-mAbs Therapeutics has a one year low of $3.55 and a one year high of $16.11.

Insider Buying and Selling at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $5.23, for a total transaction of $56,536.30. Following the sale, the insider now directly owns 202,721 shares of the company’s stock, valued at approximately $1,060,230.83. The trade was a 5.06% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 22.50% of the company’s stock.

Institutional Trading of Y-mAbs Therapeutics

Large investors have recently bought and sold shares of the company. Wells Fargo & Company MN boosted its position in Y-mAbs Therapeutics by 54.1% during the 4th quarter. Wells Fargo & Company MN now owns 17,458 shares of the company’s stock valued at $137,000 after acquiring an additional 6,131 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Y-mAbs Therapeutics by 10.4% during the third quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company’s stock valued at $399,000 after purchasing an additional 2,854 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Y-mAbs Therapeutics by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 822,309 shares of the company’s stock valued at $6,440,000 after purchasing an additional 8,820 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Y-mAbs Therapeutics by 1.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 284,540 shares of the company’s stock valued at $2,228,000 after purchasing an additional 4,963 shares during the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of Y-mAbs Therapeutics during the fourth quarter valued at approximately $46,000. 70.85% of the stock is owned by institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.